Woo-Jin Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Woo-Jin Song has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Youngmin Yun
College of Veterinary Medicine and Veterinary Medical Research Institute, Jeju National University, Jeju, Korea
28 shared publications - Hwa-Young Youn
Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea
17 shared publications - Myung-Chul Kim
Laboratory of Veterinary Clinical Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, South Korea
14 shared publications - Jongtae Cheong
Department of Veterinary Medicine, College of Veterinary Medicine and Veterinary Medical Research Institute, Jeju National University, Jeju 63243, Korea
9 shared publications - Hyunjung Park
College of Veterinary Medicine and Veterinary Medical Research Institute, Jeju National University, Jeju 63243, Korea
6 shared publications - JeongHa Lee
Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Jeju National University, Jeju 63243, South Korea
6 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (6)
Acute Levothyroxine Overdose Followed by Serial Monitoring of Total Thyroxine and Thyroid‐Stimulating Hormone in a Hypothyroid Dog
Reports of acute levothyroxine overdose in dogs are rare with limited monitoring data. An 8‐year‐old spayed female Pomeranian receiving long‐term hypothyroidism treatment presented 9 h after ingesting a one‐month supply of levothyroxine (3 mg; 1.13 mg/kg). Except for transient tachycardia, the physical examination revealed unremarkable findings. The total thyroxine (T4) level exceeded the upper limit of quantification. Levothyroxine was discontinued, and activated charcoal and intravenous fluid were administered. The dog showed normal vital signs and no further clinical abnormalities during the 5‐day hospitalisation. The total T4 concentration decreased and normalised by 73 h after the overdose. The canine thyroid‐stimulating hormone (cTSH) concentrations were initially normal but exceeded the upper reference limit at 98 h. The patient was discharged on Day 5. Two days later, levothyroxine was resumed because the dog exhibited signs of recurrent hypothyroidism with persistently elevated cTSH levels. Hypothyroidism was well‐controlled for 6 months. To our knowledge, this is the first report to document a levothyroxine overdose in a hypothyroid dog using daily total T4 and cTSH monitoring. These findings suggest that acute overdose is less severe than chronic levothyroxine exposure.
- 12 November 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (6)
Open AccessAcute Levothyroxine Overdose Followed by Serial Monitoring of Total Thyroxine and Thyroid‐Stimulating Hormone in a Hypothyroid Dog
Reports of acute levothyroxine overdose in dogs are rare with limited monitoring data. An 8‐year‐old spayed female Pomeranian receiving long‐term hypothyroidism treatment presented 9 h after ingesting a one‐month supply of levothyroxine (3 mg; 1.13 mg/kg). Except for transient tachycardia, the physical examination revealed unremarkable findings. The total thyroxine (T4) level exceeded the upper limit of quantification. Levothyroxine was discontinued, and activated charcoal and intravenous fluid were administered. The dog showed normal vital signs and no further clinical abnormalities during the 5‐day hospitalisation. The total T4 concentration decreased and normalised by 73 h after the overdose. The canine thyroid‐stimulating hormone (cTSH) concentrations were initially normal but exceeded the upper reference limit at 98 h. The patient was discharged on Day 5. Two days later, levothyroxine was resumed because the dog exhibited signs of recurrent hypothyroidism with persistently elevated cTSH levels. Hypothyroidism was well‐controlled for 6 months. To our knowledge, this is the first report to document a levothyroxine overdose in a hypothyroid dog using daily total T4 and cTSH monitoring. These findings suggest that acute overdose is less severe than chronic levothyroxine exposure.
- Open Access
- 30 June 2026
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 43 (3) , 161-166
Hematologic Improvement in Two Dogs with Suspected Refractory Precursor-Targeted Immune-Mediated Anemia Following Romiplostim-Based Therapy
- 30 June 2026
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 43 (3) , 161-166
Open AccessHematologic Improvement in Two Dogs with Suspected Refractory Precursor-Targeted Immune-Mediated Anemia Following Romiplostim-Based Therapy
- Open Access
- 30 April 2026
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 43 (2) , 79-85
Effectiveness of Darbepoetin and Iron Supplementation in Cats with Complex Chronic Diseases and Anemia: A Retrospective Study
Sungyoung Choi, Kun-Woo Kim, Jihoon Kwak, JeongHa Lee, Taeho Lee, Myung-Chul Kim, YoungMin Yun, Woo-Jin Song. J Vet Clin 2026;43:79-85. https://doi.org/10.17555/jvc.2026.43.2.79
- 30 April 2026
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 43 (2) , 79-85
Open AccessEffectiveness of Darbepoetin and Iron Supplementation in Cats with Complex Chronic Diseases and Anemia: A Retrospective Study
Sungyoung Choi, Kun-Woo Kim, Jihoon Kwak, JeongHa Lee, Taeho Lee, Myung-Chul Kim, YoungMin Yun, Woo-Jin Song. J Vet Clin 2026;43:79-85. https://doi.org/10.17555/jvc.2026.43.2.79
- Open Access
- 28 February 2026
- Published by The Korean Society of Veterinary Science (KJVR) in Korean Journal of Veterinary Research
- Vol. 66 (1) , e2
Clinical application of tadalafil in dogs with pulmonary hypertension: a retrospective study
Pulmonary hypertension (PH) is characterized by abnormally increased pressure within the pulmonary vasculature. Phosphodiesterase type 5 (PDE5) inhibitors are commonly used to manage PH, and tadalafil, a PDE5 inhibitor with a longer half-life than sildenafil, has rarely been investigated in veterinary medicine. This retrospective study analyzed medical records of dogs treated with tadalafil at the Veterinary Medical Teaching Hospital of Jeju National University between January 2021 and July 2023. Eleven dogs tentatively diagnosed with PH received tadalafil at an initial dosage of 1 mg/kg once daily and were monitored for over 4 weeks. Efficacy and adverse effects were evaluated based on history and physical examination findings. Ten dogs had previously received sildenafil, while one dog was treated with tadalafil as first‐line therapy. Nausea occurred in one case. Seven of 11 dogs achieved at least partial remission, whereas 4 showed no improvement. Notably, 8 dogs (72.7%) were receiving concomitant medications targeting the underlying diseases causing PH, which may have contributed to symptom improvement and influenced clinical outcomes. Thus, although tadalafil at 1 mg/kg once daily was generally well tolerated and appeared to provide acceptable control of PH, its efficacy should be interpreted cautiously given the small sample size. It may be particularly beneficial when the underlying diseases causing PH are adequately managed with concomitant therapies, within the context of multimodal treatment.
- 28 February 2026
- Published by The Korean Society of Veterinary Science (KJVR) in Korean Journal of Veterinary Research
- Vol. 66 (1) , e2
Open AccessClinical application of tadalafil in dogs with pulmonary hypertension: a retrospective study
Pulmonary hypertension (PH) is characterized by abnormally increased pressure within the pulmonary vasculature. Phosphodiesterase type 5 (PDE5) inhibitors are commonly used to manage PH, and tadalafil, a PDE5 inhibitor with a longer half-life than sildenafil, has rarely been investigated in veterinary medicine. This retrospective study analyzed medical records of dogs treated with tadalafil at the Veterinary Medical Teaching Hospital of Jeju National University between January 2021 and July 2023. Eleven dogs tentatively diagnosed with PH received tadalafil at an initial dosage of 1 mg/kg once daily and were monitored for over 4 weeks. Efficacy and adverse effects were evaluated based on history and physical examination findings. Ten dogs had previously received sildenafil, while one dog was treated with tadalafil as first‐line therapy. Nausea occurred in one case. Seven of 11 dogs achieved at least partial remission, whereas 4 showed no improvement. Notably, 8 dogs (72.7%) were receiving concomitant medications targeting the underlying diseases causing PH, which may have contributed to symptom improvement and influenced clinical outcomes. Thus, although tadalafil at 1 mg/kg once daily was generally well tolerated and appeared to provide acceptable control of PH, its efficacy should be interpreted cautiously given the small sample size. It may be particularly beneficial when the underlying diseases causing PH are adequately managed with concomitant therapies, within the context of multimodal treatment.
- 30 January 2026
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 24 (2) , 274-283
Clinical Efficacy and Tolerability of Sorafenib in Dogs With Advanced Carcinomas
Advanced carcinomas in dogs present significant therapeutic challenges with limited treatment options and poor prognoses. Sorafenib, a multi‐kinase inhibitor targeting RAF and receptor tyrosine kinases, has demonstrated antitumor activity and tolerability in preclinical veterinary studies; however, clinical data remain limited. This prospective, open‐label cohort study evaluated the tolerability and clinical efficacy of oral sorafenib (6 mg/kg once daily) in 24 dogs with cytologically or histologically confirmed unresectable, recurrent, or metastatic carcinomas. Tumour response was assessed using RECIST criteria, and adverse events were graded according to VCOG‐CTCAE v2.0. Stable disease at 1 month was observed in 14 of 18 evaluable dogs (77.8%), yielding an overall clinical benefit rate of 58.3%. Median time to progression and overall survival were 51 days (95% CI, 14–115) and 65 days (95% CI, 49–143), respectively. Dogs presenting with lameness ( n = 7) showed significantly longer time to progression and overall survival than those without ( p < 0.01). Adverse events occurred in 9 of 24 dogs (37.5%), primarily mild lameness (29%) and gastrointestinal signs. Weight gain at 1 month, observed in 66.7% of dogs, was significantly associated with clinical benefit ( p = 0.005; OR = 45.0; 95% CI, 1.8–1127.7). Sorafenib was well tolerated and provided measurable clinical benefit in dogs with advanced carcinomas. Lameness may represent a prognostic biomarker, and weight gain may reflect a favourable clinical response. These findings support further investigation of sorafenib and other tyrosine kinase inhibitors in veterinary oncology.
- 30 January 2026
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 24 (2) , 274-283
Clinical Efficacy and Tolerability of Sorafenib in Dogs With Advanced Carcinomas
Advanced carcinomas in dogs present significant therapeutic challenges with limited treatment options and poor prognoses. Sorafenib, a multi‐kinase inhibitor targeting RAF and receptor tyrosine kinases, has demonstrated antitumor activity and tolerability in preclinical veterinary studies; however, clinical data remain limited. This prospective, open‐label cohort study evaluated the tolerability and clinical efficacy of oral sorafenib (6 mg/kg once daily) in 24 dogs with cytologically or histologically confirmed unresectable, recurrent, or metastatic carcinomas. Tumour response was assessed using RECIST criteria, and adverse events were graded according to VCOG‐CTCAE v2.0. Stable disease at 1 month was observed in 14 of 18 evaluable dogs (77.8%), yielding an overall clinical benefit rate of 58.3%. Median time to progression and overall survival were 51 days (95% CI, 14–115) and 65 days (95% CI, 49–143), respectively. Dogs presenting with lameness ( n = 7) showed significantly longer time to progression and overall survival than those without ( p < 0.01). Adverse events occurred in 9 of 24 dogs (37.5%), primarily mild lameness (29%) and gastrointestinal signs. Weight gain at 1 month, observed in 66.7% of dogs, was significantly associated with clinical benefit ( p = 0.005; OR = 45.0; 95% CI, 1.8–1127.7). Sorafenib was well tolerated and provided measurable clinical benefit in dogs with advanced carcinomas. Lameness may represent a prognostic biomarker, and weight gain may reflect a favourable clinical response. These findings support further investigation of sorafenib and other tyrosine kinase inhibitors in veterinary oncology.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Veterinary Science
- Vol. 27 (1) , e11
Cutaneous epitheliotropic lymphoma with marked nuclear pleomorphism in a dog
Lee DH, et al. J Vet Sci. 2026 Jan;27:e11. https://doi.org/10.4142/jvs.25232
- 1 January 2026
- Published by XMLink in Journal of Veterinary Science
- Vol. 27 (1) , e11
Open AccessCutaneous epitheliotropic lymphoma with marked nuclear pleomorphism in a dog
Lee DH, et al. J Vet Sci. 2026 Jan;27:e11. https://doi.org/10.4142/jvs.25232
- Open Access
- 31 December 2025
- Published by The Korean Society of Veterinary Science (KJVR) in Korean Journal of Veterinary Research
- Vol. 65 (4) , e30
Erratum: Successful long-term management of late-stage precursor-targeted immune-mediated anemia with prednisolone and mycophenolate mofetil in a dog
- 31 December 2025
- Published by The Korean Society of Veterinary Science (KJVR) in Korean Journal of Veterinary Research
- Vol. 65 (4) , e30
Open AccessErratum: Successful long-term management of late-stage precursor-targeted immune-mediated anemia with prednisolone and mycophenolate mofetil in a dog
- Open Access
- 31 December 2025
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 42 (6) , 372-377
Suspected Immune-Mediated Etiology of Acquired von Willebrand Syndrome in a Jindo Dog
Heesoo Cho, Sungyoung Choi, JeongHa Lee, YoungMin Yun, Yubin Kim, Myung-Chul Kim, Woo-Jin Song. J Vet Clin 2025;42:372-7. https://doi.org/10.17555/jvc.2025.42.6.372
- 31 December 2025
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 42 (6) , 372-377
Open AccessSuspected Immune-Mediated Etiology of Acquired von Willebrand Syndrome in a Jindo Dog
Heesoo Cho, Sungyoung Choi, JeongHa Lee, YoungMin Yun, Yubin Kim, Myung-Chul Kim, Woo-Jin Song. J Vet Clin 2025;42:372-7. https://doi.org/10.17555/jvc.2025.42.6.372
- Open Access
- 31 October 2025
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 42 (5) , 241-251
Serum CA 15-3, miR-21, and miR-29b Levels as Diagnostic and Prognostic Biomarkers in Canine Mammary Tumors
JeongHa Lee, Myung-Chul Kim, Youngmin Yun, Woo-Jin Song. J Vet Clin 2025;42:241-51. https://doi.org/10.17555/jvc.2025.42.5.241
- 31 October 2025
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 42 (5) , 241-251
Open AccessSerum CA 15-3, miR-21, and miR-29b Levels as Diagnostic and Prognostic Biomarkers in Canine Mammary Tumors
JeongHa Lee, Myung-Chul Kim, Youngmin Yun, Woo-Jin Song. J Vet Clin 2025;42:241-51. https://doi.org/10.17555/jvc.2025.42.5.241
- Open Access
- 31 August 2025
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 42 (4) , 174-178
Hydropulsion as a Diagnostic and Palliative Technique for Nasal Disease in Dogs
Jeongyun Shin, Ujin Kim, YoungMin Yun, Woo-Jin Song. J Vet Clin 2025;42:174-8. https://doi.org/10.17555/jvc.2025.42.4.174
- 31 August 2025
- Published by The Korean Society of Veterinary Clinics in Journal of Veterinary Clinics
- Vol. 42 (4) , 174-178
Open AccessHydropulsion as a Diagnostic and Palliative Technique for Nasal Disease in Dogs
Jeongyun Shin, Ujin Kim, YoungMin Yun, Woo-Jin Song. J Vet Clin 2025;42:174-8. https://doi.org/10.17555/jvc.2025.42.4.174